1367TiP IMPRINTER: An open label, multi-center, dose escalation/expansion, phase I study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer

Category Primary study
JournalAnnals of Oncology
Year 2021
This article has no abstract
Epistemonikos ID: 911d0c21a398ab23232e6bca5295d97a468b2f9c
First added on: Feb 13, 2025